NeoGenomics, Inc. has grown revenue 12% a year over three years and 9.4% a year over five. Revenue growth, 3-year annual rate: +12% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +9.4%, growth has picked up over the last three years. Years of annual history on file: 16, FY2010 to FY2025, as filed.

NEONeoGenomics, Inc.

Healthcare

$16.35+92% 1Y

$16.35

$7.1952 weeks$19.90

Is it growing?

Good

Growing: revenue growing +11% year on year and operating margin widening (+7.5 points).

2 good, 1 without data

Revenue trend+11% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.

Margin direction+7.5 points operating

Trailing-twelve-month operating margin, -9.0% now against -16.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NEO growing?

NeoGenomics, Inc. has grown revenue 12% a year over three years and 9.4% a year over five.

+12%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +9.4%
Revenue growth, 5-year rate · +12% over three · growth has picked up over the last three years
Years of annual history on file: 16
Years of annual history on file · FY2010 to FY2025, as filed

Details›